When will the patents on MILOPHENE expire, and when will generic MILOPHENE be available?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Granata Bio Corp	MILOPHENE	clomiphene citrate	TABLET;ORAL	072196-001	Dec 20, 1988	AB	RX	No	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Milophene is an investigational drug developed by Gedeon Richter Plc. for the treatment of infertility. The drug's active pharmaceutical ingredient is clomifene citrate, a selective estrogen receptor modulator (SERM). Milophene is currently in Phase III clinical trials in several countries.

What is Milophene's Mechanism of Action and Therapeutic Potential?

Milophene (clomifene citrate) functions as a SERM by selectively binding to estrogen receptors in the hypothalamus and pituitary gland. This binding partially blocks the negative feedback of circulating estrogen, leading to an increase in the release of gonadotropin-releasing hormone (GnRH). GnRH, in turn, stimulates the pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are crucial for follicular development in the ovaries and ovulation.

The therapeutic potential of Milophene lies in its ability to induce ovulation in women who are not ovulating regularly. This is particularly relevant for conditions such as polycystic ovary syndrome (PCOS), where anovulation is a common cause of infertility. By stimulating ovulation, Milophene offers a non-surgical intervention to increase the likelihood of conception.

Key aspects of its therapeutic profile include:

Target Patient Population: Primarily women with ovulatory dysfunction, including those diagnosed with PCOS.
Clinical Indication: Treatment of infertility due to anovulation.
Expected Outcome: Increased frequency of ovulation and subsequent pregnancy rates.

What is the Current Regulatory Status and Clinical Trial Landscape for Milophene?

Gedeon Richter Plc. is actively advancing Milophene through clinical development. The drug is currently in Phase III trials, the final stage of clinical testing before regulatory submission.

Key Trial Information:

Phase: III
Sponsor: Gedeon Richter Plc.
Therapeutic Area: Infertility, Ovulatory Dysfunction
Geographic Focus: Trials are ongoing in various regions, including Europe and potentially other markets where Gedeon Richter has a commercial presence.
Primary Endpoints (Typical): Often focus on ovulation rates, pregnancy rates, and live birth rates.
Secondary Endpoints (Typical): May include cycle characteristics, adverse events, and patient-reported outcomes.

Regulatory Pathways:

Successful completion of Phase III trials is a prerequisite for seeking marketing authorization from regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The regulatory review process involves a thorough evaluation of the drug's safety and efficacy data. Given that clomifene citrate is an established compound for ovulation induction, the regulatory focus may be on demonstrating non-inferiority or superiority to existing treatments, particularly in terms of specific patient subgroups or improved safety profiles, and on the specific formulation or dosage regimen of Milophene.

What are the Market Dynamics and Competitive Landscape for Ovulation Induction Agents?

The market for ovulation induction agents is substantial, driven by increasing rates of infertility globally and the growing demand for assisted reproductive technologies (ART). Milophene operates within this established market.

Market Drivers:

Rising Infertility Rates: Factors include delayed childbearing, environmental influences, and lifestyle changes.
Advancements in ART: Increased accessibility and success rates of ART procedures.
Awareness and Diagnosis: Greater recognition and diagnosis of ovulatory disorders, particularly PCOS.
Economic Growth: Increased healthcare spending in developing economies.

Competitive Landscape:

The primary competitor for Milophene is clomifene citrate itself, which has been a first-line treatment for anovulatory infertility for decades. Several generic versions of clomifene citrate are widely available and represent the dominant treatment option due to their established efficacy and lower cost.

Other ovulation induction agents include:

Letrozole: Aromatase inhibitor, often used off-label for ovulation induction, particularly in PCOS. Studies have shown comparable or superior pregnancy rates to clomifene citrate in some populations [1].
Gonadotropins (e.g., FSH, LH): Injectable hormones used for more complex cases of infertility or when clomifene citrate is ineffective. These are generally more expensive and carry a higher risk of multiple pregnancies.

Milophene's Potential Positioning:

Gedeon Richter's strategy with Milophene likely aims to differentiate itself from existing generic clomifene citrate. This differentiation could be based on:

Improved Efficacy: Demonstrating higher ovulation or pregnancy rates in specific patient populations.
Enhanced Safety Profile: Reduced incidence of side effects, such as the "cheese effect" (endometrial thinning) associated with clomifene citrate.
Novel Formulation or Dosing Regimen: Offering a more convenient or effective way to administer the drug.
Targeted Patient Subgroups: Focusing on specific niches within the infertility market where existing treatments are less effective or well-tolerated.

The success of Milophene will depend on its ability to clearly demonstrate a clinical advantage over existing, low-cost generic clomifene citrate and off-label letrozole.

What are the Key Financials and Investment Considerations for Gedeon Richter Plc. Related to Milophene?

Gedeon Richter Plc. is a diversified pharmaceutical company with a strong focus on women's healthcare. Milophene represents a strategic investment within its existing therapeutic areas.

Company Overview:

Headquarters: Budapest, Hungary
Primary Markets: Central and Eastern Europe, Russia, CIS countries, and increasingly Western Europe and other global markets.
Therapeutic Areas: Women's Healthcare, Central Nervous System (CNS) disorders, and Cardiovascular diseases.
Revenue Streams: Prescription pharmaceuticals, OTC products, and veterinary medicines.

Milophene Specifics:

Development Stage: Phase III clinical trials. This implies significant investment in R&D, manufacturing scale-up, and regulatory affairs.
Commercialization Potential: If successful, Milophene could expand Gedeon Richter's women's healthcare portfolio and potentially capture market share from existing clomifene citrate treatments.
Investment Risks:
- Clinical Trial Failure: A significant risk at this stage. Failure to meet primary endpoints in Phase III trials would halt development.
- Regulatory Approval Hurdles: Unforeseen regulatory challenges or requests for additional data.
- Market Adoption: Competition from established generics and the need to prove a distinct clinical benefit to physicians and patients.
- Pricing and Reimbursement: Securing favorable pricing and reimbursement from healthcare payers.

Financial Impact (Hypothetical):

The financial impact of Milophene on Gedeon Richter will be determined by:

Total R&D Expenditure: Costs incurred through clinical trials, manufacturing development, and regulatory submissions.
Manufacturing Costs: Scaling up production for commercial launch.
Marketing and Sales Expenditure: Costs associated with launching and promoting the drug.
Revenue Generation: Sales volumes and pricing achieved post-approval.

For investors, the key considerations are the probability of Milophene's successful approval and its potential to contribute meaningfully to Gedeon Richter's revenue and profitability. Given the established nature of clomifene citrate, Milophene's success will hinge on demonstrating a clear and quantifiable improvement over current standards of care.

What are the Potential Risks and Mitigation Strategies for Milophene's Development and Commercialization?

The development and commercialization of any pharmaceutical product carry inherent risks. For Milophene, these risks can be categorized into clinical, regulatory, commercial, and financial aspects.

Clinical Risks:

Efficacy Not Demonstrated: Phase III trials may fail to show a statistically significant improvement in ovulation or pregnancy rates compared to placebo or active comparators.
- Mitigation: Rigorous trial design with well-defined patient populations, robust statistical analysis plans, and early-stage efficacy signals from earlier trials.
Adverse Events: An unacceptable safety profile could emerge during Phase III or post-marketing surveillance. While clomifene citrate has a known safety profile, specific formulations or patient responses may differ.
- Mitigation: Comprehensive safety monitoring protocols, dose optimization, and careful patient selection.
Multiple Pregnancies and Ovarian Hyperstimulation Syndrome (OHSS): These are known risks associated with ovulation induction agents.
- Mitigation: Strict adherence to recommended dosing and monitoring protocols, patient counseling on risks.

Regulatory Risks:

Delayed Approval: Regulatory agencies may request additional data, prolonging the review process.
- Mitigation: Proactive engagement with regulatory authorities throughout the development process, ensuring high-quality data submission.
Labeling Restrictions: The approved label may be narrower than anticipated, limiting the target patient population.
- Mitigation: Comprehensive understanding of regulatory expectations regarding indications and patient subgroups.

Commercial Risks:

Competition: Strong competition from low-cost generic clomifene citrate and increasingly from letrozole.
- Mitigation: Clearly demonstrating a superior clinical benefit (efficacy, safety, convenience) that justifies a premium price or improved patient outcomes. Targeted marketing to prescribers and patient advocacy groups.
Market Access and Reimbursement: Difficulty securing favorable pricing and reimbursement from national health systems and private payers.
- Mitigation: Generating strong health economic data demonstrating value for money. Engaging with payers early in the commercialization process.
Physician and Patient Adoption: Reluctance from physicians to switch from established treatments or from patients to adopt a new drug.
- Mitigation: Robust medical education programs, clinical data dissemination, and patient support initiatives.

Financial Risks:

High Development Costs: Phase III trials are expensive, and there is no guarantee of return on investment.
- Mitigation: Careful financial planning, phased investment, and contingency budgeting.
Post-Marketing Commitments: Requirements for post-approval studies or pharmacovigilance activities.
- Mitigation: Incorporating potential post-marketing requirements into financial and operational planning.

What is the Outlook for Milophene in the Fertility Treatment Market?

The outlook for Milophene is contingent on its successful navigation through the remaining stages of clinical development and regulatory review. The drug's ability to secure a significant market position will depend on its demonstrable advantages over existing therapies.

Key Determinants of Future Success:

Clinical Differentiation: The most critical factor. Milophene must present compelling evidence of superior efficacy, a favorable safety profile, or enhanced patient convenience compared to generic clomifene citrate and off-label letrozole. Without clear differentiation, market penetration will be challenging.
Regulatory Approval: Successful and timely approval from major regulatory bodies is a prerequisite.
Market Access and Pricing: The ability to secure favorable reimbursement from payers will directly impact accessibility and sales volumes.
Commercial Strategy: Gedeon Richter's marketing and sales efforts will be crucial for educating healthcare providers and patients about Milophene's benefits.

Scenario Analysis:

Optimistic Scenario: Milophene demonstrates statistically significant improvements in pregnancy rates and/or a superior safety profile, leading to widespread physician adoption and favorable reimbursement. This could position Milophene as a valuable second-line or even first-line option for specific patient segments.
Base Case Scenario: Milophene shows comparable efficacy to existing treatments but with some minor advantages in safety or convenience. It may carve out a niche market, particularly in regions where Gedeon Richter has a strong presence, but significant market share gains against generics will be difficult.
Pessimistic Scenario: Clinical trials fail to meet primary endpoints, or an unfavorable safety profile emerges, leading to discontinuation of development. Alternatively, regulatory hurdles or poor market access could severely limit its commercial viability.

Given that clomifene citrate is an established, low-cost therapy, Milophene will likely need to target specific patient populations or offer a unique benefit to achieve substantial commercial success. Its performance will be closely watched by investors and competitors in the infertility treatment market.

Key Takeaways

Milophene, an investigational ovulation induction agent developed by Gedeon Richter Plc., is in Phase III clinical trials. Its active ingredient, clomifene citrate, targets anovulatory infertility, primarily in women with PCOS. The drug faces intense competition from established generic clomifene citrate and off-label use of letrozole. Success hinges on demonstrating clear clinical superiority in efficacy or safety. The financial impact on Gedeon Richter will depend on R&D expenditure, successful regulatory approval, market access, and commercial adoption. Key risks include clinical trial failure, regulatory hurdles, and market competition. The drug's future outlook is cautiously optimistic, contingent on its ability to differentiate itself in a crowded market.

Frequently Asked Questions

What is the primary indication for Milophene? Milophene is being developed for the treatment of infertility due to anovulatory dysfunction.
Who is the main competitor to Milophene? The primary competitors are generic clomifene citrate and letrozole.
What phase of clinical trials is Milophene currently in? Milophene is currently in Phase III clinical trials.
What is the mechanism of action of clomifene citrate, the active ingredient in Milophene? Clomifene citrate is a selective estrogen receptor modulator that stimulates the release of gonadotropins (FSH and LH) from the pituitary gland, promoting follicular development and ovulation.
What are the key risks associated with Milophene's development? Key risks include failure to demonstrate sufficient efficacy or a favorable safety profile in Phase III trials, regulatory approval challenges, and strong market competition.

Citations

[1] Tulandi, T., & Fareed, S. (2014). Clomiphene citrate vs letrozole for ovulation induction. Fertility and Sterility, 102(6), 1507-1511.

MILOPHENE Drug Patent Profile

Which patents cover Milophene, and when can generic versions of Milophene launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Milophene

AI Deep Research

Questions you can ask:

Summary for MILOPHENE

US Patents and Regulatory Information for MILOPHENE

MILOPHENE Investment Scenario and Fundamentals Analysis